Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315093 | 0.90 | TSHR (0.73) | TSHRHSD17B10HRH4HTR2CMEN1 | |
| SCHEMBL4313523 | 0.86 | HSD17B10 (0.57) | TSHRHSD17B10HRH4HTR2CMEN1 | |
| SCHEMBL4313352 | 0.83 | TSHR (0.57) | TSHRHSD17B10HRH4MEN1POLB | |
| SCHEMBL4308187 | 0.83 | HTR2C (0.53) | TSHRHSD17B10HRH4HTR2CMEN1 | |
| SCHEMBL4307776 | 0.81 | TSHR (0.58) | TSHRHSD17B10HRH4MEN1POLB | |
| SCHEMBL6046292 | 0.80 | HTR2C (0.48) | HTR2CLTA4HHTR3A | |
| SCHEMBL4314566 | 0.77 | TSHR (0.52) | TSHRHSD17B10HRH4MEN1POLB | |
| SCHEMBL4311853 | 0.77 | TSHR (0.54) | TSHRHSD17B10HRH4HTR2CLTA4H | |
| SCHEMBL4311478 | 0.76 | HTR2C (0.45) | HTR2CLTA4HHTR3A | |
| SCHEMBL4321095 | 0.76 | TSHR (0.46) | TSHRHSD17B10HRH4HTR2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | claimed |
| US-7524590-B2 | Methods for storing holographic data and articles having enhanced data storage lifetime derived therefrom | GENERAL ELECTRIC COMPANY (US) | 2009-04-28 | — | — | US | claimed |
| WO-2007067670-A2 | METHODS FOR STORING HOLOGRAPHIC DATA AND ARTICLES HAVING ENHANCED DATA STORAGE LIFETIME DERIVED THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2007-06-14 | — | — | WO | claimed |
| US-20070127329-A1 | Methods for storing holographic data and articles having enhanced data storage lifetime derived therefrom | GENERAL ELECTRIC COMPANY (US) | 2007-06-07 | — | — | US | claimed |
| US-5639802-A | PHOTOHARDENABLE PHOTOSENSITIVE COMPOSITIONS | SPECTRA GROUP LIMITED, INC. (US) | 1997-06-17 | — | — | US | claimed |
| US-11666578-B2 | Small molecule inhibitors of CDK12/CDK13 | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230137820-A1 | PHOSPHORESCENT aNHC-BASED PLATINUM (II) COMPLEXES | Technische Universität Dresden (DE) | 2023-05-04 | — | — | US | disclosed |
| EP-3717495-B1 | PHOSPHORESCENT PLATINUM (II) ANHC COMPLEXES | UNIV DRESDEN TECH (DE) | 2021-12-29 | — | — | EP | disclosed |
| US-20210186979-A1 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-24 | — | — | US | disclosed |
| EP-3717495-A1 | PHOSPHORESCENT PLATINUM (II) ANHC COMPLEXES | Technische Universität Dresden (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019217421-A1 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-11-14 | — | — | WO | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-0408227-A1 | Photohardenable or photosoftenable compositions | THE MEAD CORPORATION (US) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | TSHR 457/4885HSD17B10 524/4885HRH4 219/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | TSHR 531/4885HSD17B10 475/4885HRH4 213/4885 |
| US-20210186979-A1 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 | CDK12, CDK1, CDK13 | TSHR 3554/4885HSD17B10 2251/4885HRH4 4493/4885 |
| US-11666578-B2 | Small molecule inhibitors of CDK12/CDK13 | CDK12, CDK1, CDK13 | TSHR 3554/4885HSD17B10 2251/4885HRH4 4493/4885 |
| US-20230137820-A1 | PHOSPHORESCENT aNHC-BASED PLATINUM (II) COMPLEXES | NDC1, ORC3, NUDC | TSHR 4255/4885HSD17B10 1084/4885HRH4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.